[New therapeutic strategies for multiple myeloma. Efficacy and cost-effectiveness analyses].
The objective of the present article is the review of the most important therapeutic innovations in the treatment of multiple myeloma in terms of efficacy and cost-effectiveness. Besides autologous transplant with peripheral-blood stem-cell, thalidomide establishes as one of the most powerful therapeutic tools in induction and maintenance treatment and together with lenalidomide and bortezomib as therapy for relapsing/refractory multiple myeloma. Considering, the last named situation thalidomide can be an adequate therapeutical option in combination with dexamethasone. Under a strictly pharmacoeconomic point of view, lenalidomide and bortezomib seem to be additional alternatives in patients previously treated with thalidomide.
García Quetglas
Emilio
E
Servicio de Farmacología Clínica, Clínica Universitaria de Navarra, Pamplona, Navarra. España. egquetglas@unav.es
Azanza Perea
José Ramón
JR
Lecumberri Villamediana
Ramón
R
D003362:Cost-Benefit Analysis; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000191:economics; D012008:Recurrence